Financing ·
OS Therapies Incorporated entered into a securities purchase agreement for an August Private Placement of senior…
OSTXOS Therapies Inc
OS Therapies Incorporated entered into a securities purchase agreement for an August Private Placement of senior secured convertible promissory notes with an aggregate subscription amount of up to $10,000,000. The company consummated the initial closing on August 10, 2026, issuing Notes in an aggregate principal amount of $5,405,405.42, along with common stock and warrants. This transaction included the automatic conversion of a previously issued $2,200,000 bridge convertible promissory note into new Notes and equity securities. The Notes bear 9.0% annual interest, mature nine months after funding, and are convertible at $2.05 per share. Warrants to purchase common stock were issued with an exercise price of $2.85 per share for the first tranche. Proceeds will fund clinical development, regulatory activities, working capital, and general corporate purposes. OS Therapies operates in the biotechnology industry, focusing on the discovery and development of novel therapies.